Table 3 Multivariable analysis for the association of selected patient and disease characteristics with PFS and OS for entire patient population.
PFS | OS | |||||
|---|---|---|---|---|---|---|
Variables | N (event N) | HR (95% CI) | P-value | N (event N) | HR (95% CI) | P-value |
Active EMD | 0.005 | 0.033 | ||||
No | 105 (49) | 1.00 (reference) | 105 (49) | 1.00 (reference) | ||
Yes | 47 (40) | 2.12 (1.26–3.6) | 47 (40) | 2.09 (1.06–4.12) | ||
Age | 0.353 | 0.136 | ||||
≤65 | 87 (57) | 1.00 (reference) | 87 (57) | 1. 00 (reference) | ||
>65 | 65 (43) | 0.79 (0.48–1.3) | 65 (43) | 0.59 (0.30–1.18) | ||
ECOG PS | 0.483 | 0.024 | ||||
2–4 | 20 (14) | 1.00 (reference) | 20 (14) | 1.00 (reference) | ||
0–1 | 132 (75) | 0.75 (0.33–1.7) | 132 (75) | 0.35 (0.14–0.87) | ||
Cytogenetics | 0.039 | 0.16 | ||||
Standard risk | 71 (59) | 1.00 (reference) | 71 (59) | 1.00 (reference) | ||
High risk | 49 (41) | 1.77 (1.03–3.0) | 49 (41) | 1.60 (0.83–3.08) | ||
Penta-refractory status | 0.099 | 0.509 | ||||
No | 94 (62) | 1.00 (reference) | 94 (62) | 1.00 (reference) | ||
Yes | 58 (38) | 1.60 (0.92–2.8) | 58 (38) | 0.77 (0.36–1.65) | ||
Prior BCMA therapy | <0.001 | 0.149 | ||||
No | 127 (84) | 1.00 (reference) | 127 (84) | 1.00 (reference) | ||
Yes | 25 (16) | 2.76 (1.52–5.0) | 25 (16) | 1.17 (0.83–3.55) | ||
CAR T product | 0.043 | 0.829 | ||||
Cilta-cel | 44 (29) | 1.00 (reference) | 44 (29) | 1.00 (reference) | ||
Ide-cel | 108 (81) | 2.19 (1.02–4.7) | 108 (81) | 0.91 (0.38–2.15) | ||
Baseline CRP | 0.507 | 0.774 | ||||
High | 55 (36) | 1.00 (reference) | 55 (36) | 1.00 (reference) | ||
Low | 97 (64) | 1.20 (0.7–2.0) | 97 (64) | 0.9 (0.46–1.79) | ||
Baseline ferritin | 0.049 | |||||
High | 90 (59) | 1.00 (reference) | 90 (59) | 1.00 (reference) | 0.106 | |
Low | 62 (41) | 0.52 (0.28–1.0) | 62 (41) | 0.50 (0.22–1.16) | ||
